I-HBD1 Peptide Program for bone diseases

Company   Alize Pharma III SAS
Program   I-HBD1, peptide with bone anabolic properties for the treatment of osteoporosis and other bone diseases
Stage of development   Lead optimization
Status   Unpartnered

Sofimac Partners (Emergence Innovation 1)

initiative Octalfa

Sham Innovation Santé

RhônesAlpes Création

Crédit Agricole Création

TAB Consulting



The I-HBD1 program aims to optimize and develop a new peptide derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2), as a new bone anabolic agent.

In vitro and in vivo studies have shown that this peptide can induce the formation of bone tissue by stimulating osteoblast differentiation and inhibiting osteoclast differentiation (see references below). This new mechanism of action is unique and may potentially lead to the development of a new therapeutic anabolic approach in treating osteoporosis and several other diseases associated with impaired bone metabolism.


The I-HBD1 project is being conducted in collaboration with New Paradigm Therapeutics, a spin-off company of the University of North Carolina at Chapel Hill founded by Professor David Clemmons.


The International Osteoporosis Foundation estimates that osteoporosis affects more than 200 million people worldwide and causes almost 9 million fractures each year. The global market for osteoporosis drugs was estimated at over $8.3 billion in 2014, with significant growth expected in the coming years. The current treatments are mostly anti-resorptive therapies, so there is an unmet need for safer, more cost-effective anabolic therapies that are able to build new bone for these patients.



  • Xi G, Wai C, DeMambro V, Rosen CJ, Clemmons DR. IGFBP-2 Directly Stimulates Osteoblast Differentiation. J Bone Miner Res. 2014 Nov; 29(11):2427-38
  • Xi G, Solum MA, Wai C, Maile LA, Rosen CJ, Clemmons DR. The Heparin-Binding Domains of IGFBP-2 Mediate Its Inhibitory Effect on Preadipocyte Differentiation and Fat Development in Male Mice. Endocrinology. 2013 Nov;154(11):4146-57.
  • Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012 Oct;32(20):4116-30.
  • DeMambro VE, Maile L, Wai C, Kawai M, Cascella T, Rosen CJ, Clemmons D. Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res. 2012 Feb;27(2):390-400.
  • Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, Bouxsein ML, Beamer WG, Clemmons DR, Rosen CJ. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. 2011 Apr 22;286(16):14670-80.
  • DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. Gender-specific changes in bone turnover and skeletal architecture in IGFBP-2-null mice. Endocrinology. 2008 May;149(5):2051-61.
  •  Shen X, Xi G, Wai C, Clemmons DR: The Coordinate Cellular Response to Insulin-like Growth Factor-I (IGF-I) and Insulin-like Growth Factor-binding Protein-2 (IGFBP-2) Is Regulated through Vimentin Binding to Receptor Tyrosine Phosphatase β (RPTPβ). J Biol Chem. 2015 May 1;290(18):11578-90.